AbbVie Terminates CAR-T Therapy Collaboration with Caribou Biosciences

Disclaimer: Due to limited proficiency, errors are inevitable, and some information may not be the most up-to-date. Feel free to point out in the comments. This article only introduces drugs related to healthcare and is not a recommendation of treatment plans (if involved). This article does not constitute any investment advice.

2023Year9Month26Day,Caribou BiosciencesRevealed, AbbVie(AbbVie) TerminatedAndCompanyDevelopment TwoNew Target UniversalCAR-TCooperation in therapy.AbbVie stated that this is based on the company'sStrategic FocusDecisive。

AbbVie prepaid $40 million to this startup in 2021 and committed to providing up to $300 million in R&D and registration milestone payments for two novel target universal CAR-T therapies.AbbVie will also use Caribou The Next GenerationCas12a CRISPRHybrid RNA-DNA (chRDNA)Genome editing and cell therapy technologies to research and develop two novel approaches targeting AbbVie-specified pointsCAR-TCell Therapy.AbbVieWill be responsible for the clinical development, commercialization, and manufacturing of cell therapy, whileCaribouWill conduct preclinical research, development, and manufacturing of the therapy.

This termination is one of AbbVie's recent abandonments of a series of oncology projects.8Month,AbbVieAbandoned two early antibody-drug conjugates. Then, it abandonedCompletedCorrectHarpoon Therapeutics BCMATargeted Multiple Myeloma DrugsHPN217The global exclusive license option.9Month,AbbVie alsoTerminated the partnership with I-Mab in CD47 Cooperation in pharmaceuticals.

CaribouIs produced byCRISPR-Cas9Technical LeaderJennifer DoudnaFounded as a co-founder.DoudnaDue to and PartnerEmmanuelle CharpentierTogether inCRISPR-Cas9Gained prominence for a major breakthrough in gene editing technology,2016Year Award“World Outstanding Woman Scientist Achievement Award”, and obtain2020-year Nobel Prize in Chemistry. The biotechnology company usesCRISPRHeterozygousRNA-DNA (chRDNA)Guiding Technology，Can guide better than any guideRNAMolecules all require precise genome editing.

2023Year7Month,Caribou BiosciencesAnnouncement released stating Pfizer has been obtained2500Million USD Equity Investment.According to the terms of the Securities Purchase Agreement signed by the two companies, Pfizer purchased at a price per share of5.33Purchased at a price of USD4690431ThighCaribouCommon Stock，For its another projectCB-011, which is an experimental treatment for multiple myelomaBCMATargetedCAR-TTherapy. After the news was released,CaribouImmediately surged, and as of this week's closing, its stock price has reached7.26Dollar/Thigh, roughly estimated,PfizerThis investment has already been made.25%Floating Profit.

Currently, Caribou Total4Pipeline, among which3Amount forCAR-T Therapy,1Amount forCAR-NK Therapy.3PaymentCAR-T The therapies are all targeted at hematologic malignancies, among which the fastest progress isCB-010, used for treatmentBCellular Non-Hodgkin Lymphoma, Currently Ongoing1Phase clinical trial.CB-011TargetedBCMA, used for the treatment of multiple myeloma, also in1In Phase Clinical Trials。CB-012 TargetedCD137, for the treatment of acute myeloid leukemia, is currentlySubmit Clinical Trial Application。

Caribou Biosciences' R&D Pipeline